In our cohort of patients, there were no cases of severe hyperkalemia or clinically significant drug-induced liver injury that required stopping the medication, even with concurrent use of SGLT2 inhibitors in five patients, corticosteroids/immunosuppressants in four patients, and a history of MRA use in one patient. Here, SLC5A2 is linked to Hyperkalemia.